Trials / Completed
CompletedNCT00237913
Schizophrenia Trial of Aripiprazole
A Multicenter, Randomized, Naturalistic, Open-Label Study Between Aripiprazole and Standard of Care in the Management of Community-Treated Schizophrenic Patients (Schizophrenia Trial of Aripiprazole - STAR)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 700 (planned)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Aripiprazole will show improved effectiveness over the standard of care treatment with one of three atypical antipsychotics (olanzapine, quetiapine and risperidone).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aripiprazole | Tablets, Oral, 10 - 30 mg, Once daily, 26 weeks. |
| DRUG | Olanzapine or Quetiapine or Risperidone | Olanzapine: Tablets, Oral, 5-20 mg, Once daily, 26 weeks. OR Quetiapine: Tablets, Oral, 100-800 mg, Once daily, 26 weeks. OR Risperidone: Tablets, Oral, 2-8 mg, Once daily, 26 weeks. |
Timeline
- Start date
- 2004-07-01
- Primary completion
- 2005-08-01
- Completion
- 2005-08-01
- First posted
- 2005-10-13
- Last updated
- 2013-11-08
Locations
33 sites across 9 countries: Austria, Czechia, Denmark, Finland, France, Germany, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00237913. Inclusion in this directory is not an endorsement.